Eli Lilly’s stock jumps
Digest more
Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...
Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...
The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...
By Mrinalika Roy and Bhanvi Satija (Reuters) -As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release ...
Zacks Investment Research on MSN
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...
Eli Lilly and Company (NYSE: LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback